ARTICLES BY LOUIS

• The Hardest Job In All BioPharma: The CTO

  4/4/2022

  In this final look at Chief Technology Officers, all readers will find leadership lessons. CTOs are asking: What do we need to grow into our expanded roles? Top of the agenda: "Connecting as human beings, as innovative and committed leaders, serving all our stakeholders.” 

• The Incredible Story Of An Outsourcing Phenom

  4/1/2022

  In 1996, “while in grad school at MIT, my professor tossed me into the back of a truck along with the chemicals, and moved to The Scripps Research Institute in San Diego.” So recalls Kent Pryor on how he would wind up a component of the Southern California biotechnology boom, and an outsourcing phenom.

• Controlling Time: The Secret To Manufacturing

  3/29/2022

  An experienced CEO is undertaking a manufacturing risk and opportunity strategy. He's included CDMOs and other external experts in the analysis. That analysis now sits before the board. Key is how much capacity to build, how much to outsource. The main object is to control time.

• Awards, Revelations, Outsourcing For Success

  3/25/2022

  Nobody benefits if we can't continue to partner optimally for drug development and manufacturing activities. Here's our tangible assistance in ensuring just the opposite — that you have tools to select the right CDMOs to bring you prosperity, and new drugs and therapies to your patients. 

• Hire Your CTO Now, Then Get Help At Your CDMO

  3/21/2022

  Part 2 of our dive into the growing role of the Chief Technology Officer. We cover how and when to hire for the position, and how CDMOs can assist your CTO once on board.

• Optimized Collaborations From R&D To Manufacturing

  3/14/2022

  Paul Peter Tak, has been a professor, founded/chaired organizations and biopharma companies, and spent years at GSK before becoming CEO, Candel Therapeutics. He’s formed scientific liaisons and outsourcing partnerships at every phase of drug discovery, development, and manufacturing. Here’s one of those elements for each of these steps. 

• If You're Outsourcing, Your CTO Probably Needs A Hug

  3/7/2022

  You might want to check in on your Chief Technology Officer. “They’re at the center of the storm,” says a biopharma-industry consultant focused on the modern-day CTO. The role has become critical to a company’s success, impacts across the enterprise, and has become highly pressurized.

• Just In Case of War: Back-Integrated Outsourcing

  3/4/2022

  Pandemics, now war. Based on comments from Scott Zook, Primmune Therapeutics, Chief Editor Louis Garguilo analyzes impacts, possible reactions, and particularly de-risking strategies for our development and manufacturing outsourcing industry.

• Big CDMOs Back On Emerging Biopharma Radar

  2/28/2022

  Are established CDMOs making a new play for emerging biopharma customers? COVID-19 induced supply-chain dynamics (and pricing) had Big CDMO concentrating on different customers, providing opportunities for emerging service providers. But once again, we’re sensing the winds of change. 

• Outsourcing Also Starts With the Patient

  2/21/2022

  Whether you develop and manufacture your drug or therapy in-house or at CDMOs, decisions start with patients. This report provides details such as "the ratio of the incidence to prevalence of patients for a given disease" is a calculation for capital expenditures, including to build a manufacturing facility.